BlackRock Advisors LLC increased its stake in Cepheid (NASDAQ:CPHD) by 11.3% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 144,136 shares of the company’s stock after buying an additional 14,593 shares during the period. BlackRock Advisors LLC owned about 0.20% of Cepheid worth $4,432,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of CPHD. Global Thematic Partners LLC bought a new stake in shares of Cepheid during the second quarter valued at $27,674,000. UBS Asset Management Americas Inc. boosted its stake in shares of Cepheid by 366.8% in the second quarter. UBS Asset Management Americas Inc. now owns 991,633 shares of the company’s stock valued at $30,493,000 after buying an additional 779,199 shares during the last quarter. Granahan Investment Management Inc. MA boosted its stake in shares of Cepheid by 63.6% in the first quarter. Granahan Investment Management Inc. MA now owns 847,900 shares of the company’s stock valued at $28,286,000 after buying an additional 329,500 shares during the last quarter. Eagle Asset Management Inc. bought a new stake in shares of Cepheid during the second quarter valued at $8,586,000. Finally, Bogle Investment Management L P DE bought a new stake in shares of Cepheid during the first quarter valued at $7,096,000. 95.27% of the stock is currently owned by institutional investors.
Cepheid (NASDAQ:CPHD) opened at 52.82 on Wednesday. The firm’s market capitalization is $3.86 billion. Cepheid has a 52-week low of $25.09 and a 52-week high of $53.91. The company has a 50 day moving average price of $50.53 and a 200 day moving average price of $36.56.
Cepheid (NASDAQ:CPHD) last released its quarterly earnings data on Thursday, July 28th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.19. The business earned $146 million during the quarter, compared to analysts’ expectations of $145.82 million. Cepheid had a negative net margin of 8.78% and a negative return on equity of 10.20%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.06) EPS. On average, equities analysts forecast that Cepheid will post $0.33 EPS for the current fiscal year.
CPHD has been the topic of several analyst reports. Robert W. Baird cut Cepheid from an “outperform” rating to a “neutral” rating and set a $53.00 price objective on the stock. in a research note on Monday, September 12th. Jefferies Group upped their target price on Cepheid from $28.00 to $34.00 and gave the company a “hold” rating in a research note on Wednesday, August 17th. Needham & Company LLC cut Cepheid from a “buy” rating to a “hold” rating in a research note on Tuesday, September 6th. Piper Jaffray Cos. cut Cepheid from an “overweight” rating to a “neutral” rating in a research note on Tuesday, September 6th. Finally, Craig Hallum cut Cepheid from a “buy” rating to a “hold” rating in a research note on Tuesday, September 6th. Sixteen equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $41.36.
In other news, VP Scott A. Campbell sold 746 shares of Cepheid stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $36.71, for a total transaction of $27,385.66. Following the completion of the sale, the vice president now directly owns 10,721 shares of the company’s stock, valued at approximately $393,567.91. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 4.16% of the company’s stock.
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Want to see what other hedge funds are holding CPHD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cepheid (NASDAQ:CPHD).
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.